Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obesity Drug Development To Be Discussed By Advisory Committee Sept. 8

This article was originally published in The Pink Sheet Daily

Executive Summary

The Endocrinologic & Metabolic Drugs Advisory Committee will consider comments on FDA's obesity drug guidance which include reducing the number of subjects required to evaluate a drug's safety profile and broadening inclusion criteria.

You may also be interested in...



Comparative Trials Of Obesity Drugs Sought By FDA

Agency also wants long-term studies on older drugs and combinations of approved therapies. FDA will hold an advisory committee meeting to discuss potential changes to its 1996 draft guidance on weight-loss drugs.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Changes To The NHS: How Can Pharma Best Position Itself?

The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel